Vident Investment Advisory, LLC Fate Therapeutics Inc Transaction History

Vident Investment Advisory, LLC

$0
Q3 2023

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.24 - $11.12 $11,961 - $31,369	2,821 Added 5.11%	58,045 $330,000
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $199,901 - $483,129	20,274 Added 58.01%	55,224 $557,000
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $17,084 - $29,280	-812 Reduced 2.27%	34,950 $723,000
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $240,741 - $573,960	13,540 Added 60.93%	35,762 $886,000
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $110,253 - $224,000	3,716 Added 20.08%	22,222 $862,000
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $96,780 - $130,159	2,023 Added 12.27%	18,506 $1.08 Million
Q3 2021 Nov 12, 2021	SELL	$59.27 - $95.73 $69,820 - $112,769	-1,178 Reduced 6.67%	16,483 $977,000
Q2 2021 Aug 13, 2021	BUY	$67.25 - $92.52 $56,557 - $77,809	841 Added 5.0%	17,661 $1.53 Million
Q1 2021 May 14, 2021	SELL	$72.16 - $117.4 $4,979 - $8,100	-69 Reduced 0.41%	16,820 $1.39 Million
Q4 2020 Feb 08, 2021	SELL	$38.09 - $100.95 $943,908 - $2.5 Million	-24,781 Reduced 59.47%	16,889 $1.54 Million
Q3 2020 Nov 12, 2020	SELL	$30.41 - $40.5 $88,493 - $117,855	-2,910 Reduced 6.53%	41,670 $1.67 Million
Q2 2020 Jul 17, 2020	SELL	$20.21 - $35.23 $653,065 - $1.14 Million	-32,314 Reduced 42.02%	44,580 $1.53 Million
Q1 2020 May 12, 2020	SELL	$17.28 - $31.88 $82,961 - $153,055	-4,801 Reduced 5.88%	76,894 $1.71 Million
Q4 2019 Feb 11, 2020	BUY	$13.39 - $20.73 $17,058 - $26,410	1,274 Added 1.58%	81,695 $1.6 Million
Q3 2019 Nov 13, 2019	SELL	$15.47 - $22.5 $35,550 - $51,705	-2,298 Reduced 2.78%	80,421 $1.25 Million
Q2 2019 Aug 12, 2019	SELL	$15.61 - $20.44 $212,233 - $277,902	-13,596 Reduced 14.12%	82,719 $1.68 Million
Q1 2019 May 08, 2019	SELL	$13.15 - $18.71 $45,748 - $65,092	-3,479 Reduced 3.49%	96,315 $1.69 Million
Q4 2018 Feb 14, 2019	SELL	$11.48 - $16.98 $1.09 Million - $1.61 Million	-94,906 Reduced 48.74%	99,794 $1.28 Million
Q3 2018 Nov 14, 2018	SELL	$8.75 - $16.29 $113,540 - $211,379	-12,976 Reduced 6.25%	194,700 $3.17 Million
Q2 2018 Aug 14, 2018	BUY	$9.16 - $13.48 $1.9 Million - $2.8 Million	207,676 New	207,676 $2.36 Million

Others Institutions Holding FATE

# of Institutions

177

Shares Held

113M

Call Options Held

53.7K

Put Options Held

Redmile Group, LLC San Francisco, CA

13.2M
Shares

$17.1 Million
3.01% of portfolio
Vanguard Group Inc Valley Forge, PA

10.4M
Shares

$13.5 Million
0.0% of portfolio
Black Rock Inc. New York, NY

10.1M
Shares

$13.2 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

5.57M
Shares

$7.24 Million
0.72% of portfolio
State Street Corp Boston, MA

5.25M
Shares

$6.83 Million
0.0% of portfolio

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $126M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Investment Advisory, LLC with notifications on news.

Account